Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3999085 | 0.83 | KCNH3 (0.47) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 | |
| SCHEMBL4594822 | 0.76 | ALDH1A1 (0.48) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 | |
| SCHEMBL5342232 | 0.74 | RAB9A (0.50) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 | |
| SCHEMBL5342235 | 0.74 | RAB9A (0.50) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 | |
| SCHEMBL5377321 | 0.74 | RAB9A (0.50) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 | |
| Hydrochloric Acid SCHEMBL5388102 | 0.73 | RAB9A (0.49) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 | |
| SCHEMBL9359370 | 0.72 | TDP1 (0.54) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 | |
| SCHEMBL4424175 | 0.71 | DHODH (0.48) | CYP1A2ALDH1A1CYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL8059377 | 0.71 | CYP2C9 (0.51) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 | |
| SCHEMBL8059374 | 0.71 | CYP2C9 (0.51) | CYP1A2ALDH1A1CYP2C19HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9889115-B2 | Fitness assay and associated methods | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-13 | — | — | US | disclosed |
| EP-1088098-B2 | FITNESS ASSAY AND METHODS FOR REDUCING RESISTANCE OF HIV TO THERAPY | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-01-09 | — | — | US | disclosed |
| US-8597876-B2 | Method of treating HIV infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-12-03 | — | — | US | disclosed |
| US-8003627-B2 | Urokinase inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2011-08-23 | — | — | US | disclosed |
| US-7981875-B2 | Treating pancreatic cancer by administering cardenolide uscharin extracted from Calotropis procera plants | UNIBIOSCREEN S.A. (BE) | 2011-07-19 | — | — | US | disclosed |
| EP-2336134-A1 | Fitness assay and methods for reducing resistance of HIV to therapy | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1088098-B1 | MEDICAMENT FOR TREATING HIV-INFECTED MAMMALS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| CN-100516083-C | Glycosylated steroid derivatives with anti-migratory activity | UNIBIOSCREEN S A BRUSSELS PRIV (BE) | 2009-07-22 | — | — | CN | disclosed |
| EP-1458447-A2 | COMBINATION OF CYTOCHOME P 450 DEPENDENT PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004076433-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076434-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004055039-A1 | STEROID COMPOUNDS WITH ANTI-TUMOR ACTIVITY | UNIBIOSCREEN S.A. (BE) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004033465-A1 | 2' OXO-VORUSCHARIN AND DERIVATIVES THEREOF | UNIBIOSCREEN S.A. (BE) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408043-A1 | 2''oxo-voruscharin and analogues thereof | Unibioscreen S.A. (BE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003049746-A2 | COMBINATION OF CYTOCHOME P450 DEPENDENT PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2003-06-19 | — | — | WO | disclosed |
| EP-1088098-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND SOCIAL SERVICES (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067254-A2 | MULTI-DRUG RESISTANT RETROVIRAL PROTEASE INHIBITORS AND USE THEREOF | THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067417-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | CPS1, CTSS, TST | CYP1A2 1722/4885ALDH1A1 1735/4885CYP2C19 294/4885 |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | CYP1A2 1010/4885ALDH1A1 1840/4885CYP2C19 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.